CG Oncology, Inc. CGON
What the 10-K filed Feb 27, 2026 says off the balance sheet
10-K notesRisks that are not on the face of the balance sheet. Tickdelta picks sentences with specifics and quotes them as filed. New marks a sentence with nothing like it in the 10-K filed Mar 28, 2025.
Big customers
Customers the company names as a large share of revenue or receivables (it must name any worth 10% of revenue).
No specific sentence about this in the 10-K.
Key suppliers
Parts or manufacturing that depend on one or a few suppliers.
New “In addition, there are a limited number of manufacturers capable of manufacturing viral therapies such as cretostimogene, and therefore any need to switch third-party manufacturers, including Biovire, may result in development and commercialization delays and increase our operating costs.”
Read it in the 10-K
New “In addition, HHS has been empowered to negotiate the price to negotiate the price of certain single-source biologics that have been on the market for at least eleven (11) years covered under Medicare as part of the Medicare Drug Price Negotiation Program.”
Read it in the 10-K
Lawsuits and legal claims
Pending cases, settlements and what the company has set aside for them.
“Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.”
Read it in the 10-K
New “(ANI) filed a complaint against the Company in the Superior Court of the State of Delaware seeking (i) a declaratory judgment that a provision in an assignment and technology transfer agreement between the Company and ANI, dated November 15, 2010 (the ANI Agreement), obligates the Company to pay ANI a royalty on certain “net sales” of cretostimogene, and (ii) compensatory damages alleging the Company was unjustly enriched by obtaining the benefit of certain non-patent assets under the ANI Agreement without paying adequate consideration to ANI.”
Read it in the 10-K
New “On July 29, 2025, a jury entered a verdict in favor of the Company, unanimously rejecting all of ANI's claims for unjust enrichment damages.”
Read it in the 10-K
“On March 4, 2024, a complaint was filed against the Company in the Superior Court of the State of Delaware by ANI Pharmaceuticals, Inc. seeking a declaratory judgement that a provision in an assignment and technology transfer agreement between the Company and ANI, dated November 15, 2010 (the ANI Agreement), obligates the Company to pay ANI a royalty on certain “net sales” of cretostimogene, and (ii) compensatory damages alleging the Company was unjustly enriched by obtaining the benefit of certain non-patent assets under the ANI Agreement without paying adequate consideration to ANI.”
Read it in the 10-K
Guarantees and indemnities
Promises to pay someone else's debts or losses if they cannot.
No specific sentence about this in the 10-K.
Debt covenants
Conditions in loan agreements that, if broken, can make debt due early.
No specific sentence about this in the 10-K.
Commitments off the balance sheet
Contracts the company must pay for later: purchase obligations, take-or-pay deals.
No specific sentence about this in the 10-K.
Companies it names
Tracked companies that its latest 10-K or its 8-Ks of the last year call a customer or a supplier.
No other tracked company is named as a customer or a supplier in the latest filings.
Companies that name it
Tracked companies whose latest 10-K or 8-Ks call it a customer or a supplier.
No other tracked company names it as a customer or a supplier in the latest filings.
Sentences are chosen by their words, not read by AI, so some can be off topic. Always check the filing. Open the 10-K
Sources
The notes to the financial statements, Legal Proceedings and the MD&A of the latest 10-K (and, for customers and suppliers, Business and Risk Factors), quoted as filed.
Also
Debt: the debt note in numbers.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CGON/export.csv") into a cell.